Evidence map›Paper›PMID 36849161›Full record

Trial reportNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.

Matthew A Weir, Michael Walsh, Meaghan S Cuerden, Jessica M Sontrop, Bradley L Urquhart, Yong Jin Lim, Laura C Chambers, Amit X Garg

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02369549 (Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02369549 phase3completednot on this map

Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2015 to 2020Enrolled518ConditionsChronic Kidney DiseaseArmsMicro-particle Curcumin, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Matthew A WeirDivision of Nephrology, Department of Medicine, Western University, London, ON, Canada.
Michael WalshDepartments of Medicine and Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada.
Meaghan S CuerdenLondon Health Sciences Centre, London, ON, Canada.
Jessica M SontropLondon Health Sciences Centre, London, ON, Canada.
Bradley L UrquhartDivision of Nephrology, Department of Medicine, Western University, London, ON, Canada.ORCID 0000-0001-8324-1472
Yong Jin LimDepartment of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Laura C ChambersLondon Health Sciences Centre, London, ON, Canada.
Amit X GargDivision of Nephrology, Department of Medicine, Western University, London, ON, Canada.
Western University · CALondon Health Sciences Centre · CAPopulation Health Research Institute · CA

Funding

CIHR CIHR365629
6 · The paper itself

Abstract

backgroundCurcumin is a commonly used herbal supplement with anti-inflammatory and anti-fibrotic properties. Animal studies and small human trials suggest that curcumin reduces albuminuria in patients with chronic kidney disease (CKD). Micro-particle curcumin is a new, more bioavailable formulation of curcumin.

methodsTo determine whether micro-particle curcumin versus placebo slows the progression of albuminuric CKD we conducted a randomized, double-blind, placebo-controlled trial with 6-month follow-up. We included adults with albuminuria [a random urine albumin-to-creatinine ratio >30 mg/mmol (265 mg/g) or a 24-h urine collection with more than 300 mg of protein] and an estimated glomerular filtration rate (eGFR) between 15 and 60 mL/min/1.73 m2 within the 3 months before randomization. We randomly allocated participants 1:1 to receive micro-particle curcumin capsules (90 mg/day) or matching placebo for 6 months. After randomization, the co-primary outcomes were the changes in albuminuria and the eGFR.

resultsWe enrolled 533 participants, but 4/265 participants in the curcumin group and 15/268 in the placebo group withdrew consent or became ineligible. The 6-month change in albuminuria did not differ significantly between the curcumin and placebo groups [geometric mean ratio 0.94, 97.5% confidence interval (CI) 0.82 to 1.08, P = .32]. Similarly, the 6-month change in eGFR did not differ between groups (mean between-group difference -0.22 mL/min/1.73 m2, 97.5% CI -1.38 to 0.95, P = .68).

conclusionsNinety milligrams of micro-particle curcumin daily did not slow the progression of albuminuric CKD over 6 months.

trial registrationClinicalTrials.gov Identifier: NCT02369549.

Indexed as

CurcuminRenal Insufficiency, ChronicAdultAlbuminuriaDisease ProgressionDouble-Blind MethodGlomerular Filtration RateHumansCurcuminalbuminuriachronic renal insufficiencyclinical trialcurcuminGFR

Identifiers

PMID36849161
PMCPMC10539205
OpenAlexW4322485602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.